Department: Department of Chemistry Birla Institute of Technology and Science, Pilani 333 031, India.
Department: Department of Natural Sciences, University of Houston - Downtown, Houston, TX 77002, USA.
Bioorg Med Chem Lett. 2021 Apr 1;37:127842. doi: 10.1016/j.bmcl.2021.127842. Epub 2021 Feb 5.
A series of novel indolyl-α-keto-1,3,4-oxadiazole derivatives have been synthesized by employing molecular iodine-mediated oxidative cyclization of acylhydrazones. In vitro anti cell proliferation activity of these derivatives against various cancer cells lines such as human lymphoblast (U937), leukemia (Jurkat & SB) and human breast (BT474) was investigated. Among the synthesized indolyl-α-keto-1,3,4-oxadiazoles 19a-p, only one compound (19e) exhibited significant antiproliferative activity against a panel of cell lines. The compound 19e with 3,4,5-trimethoxyphenyl motif, endowed strong cytotoxicity against U937, Jurkat, BT474 and SB cancer cells with IC values of 7.1, 3.1, 4.1, and 0.8 µM, respectively. Molecular docking studies suggested a potential binding mode for 19e in the colchicine binding site of tubulin. When tested for in vitro tubulin polymerizaton, 19e inhibited tubulin polymezations (IC = 10.66 µM) and induced apoptosis through caspase 3/7 activation. Further, the derivative 19e did not cause necrosis when measured using lactate dehydrogenase assay.
一系列新型吲哚基-α-酮-1,3,4-噁二唑衍生物通过酰腙的分子碘介导的氧化环化合成。研究了这些衍生物对各种癌细胞系(如人淋巴母细胞(U937)、白血病(Jurkat 和 SB)和人乳腺癌(BT474))的体外抗细胞增殖活性。在所合成的吲哚基-α-酮-1,3,4-噁二唑 19a-p 中,只有一种化合物(19e)对一系列细胞系表现出显著的抗增殖活性。具有 3,4,5-三甲氧基苯基结构的化合物 19e 对 U937、Jurkat、BT474 和 SB 癌细胞表现出强烈的细胞毒性,IC 值分别为 7.1、3.1、4.1 和 0.8µM。分子对接研究表明,19e 在微管蛋白的秋水仙碱结合位点具有潜在的结合模式。当在体外测试微管蛋白聚合时,19e 抑制微管蛋白聚合(IC=10.66µM)并通过 caspase 3/7 激活诱导细胞凋亡。此外,在用乳酸脱氢酶测定法测量时,该衍生物 19e 不会引起坏死。